News & Updates
Filter by Specialty:
Updated ASCEMBL results boost asciminib potential for CML
In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).
Updated ASCEMBL results boost asciminib potential for CML
28 Jun 2022
Five-test universal HBV screening strategy most cost-effective in China
A nationally representative study led by researchers from the University of Hong Kong and Xi’an Jiaotong University Health Science Centre, China, has shown that a five-test (ie, serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb) universal screening strategy in people aged 18–70 years is the most cost-effective hepatitis B virus (HBV) screening option in China.
Five-test universal HBV screening strategy most cost-effective in China
28 Jun 2022
Insomnia in children with ADHD affects daytime behaviour and cognitive functioning
Insomnia may play a role in manifestation of attention deficit hyperactivity disorder (ADHD) symptoms and has a negative effect on cognitive abilities of children with ADHD, according to a cross-sectional study by the University of Hong Kong (HKU), the Chinese University of Hong Kong (CUHK) and Alice Ho Miu Ling Nethersole Hospital.
Insomnia in children with ADHD affects daytime behaviour and cognitive functioning
28 Jun 2022
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.
